• The ODELIA research project aims to “overcome the obstacles of collecting information on patients’ health with guarantees” in order to advance early, better and more accurate diagnosis and treatment.

The Ribera healthcare group is participating in a European research project, christened ODELIA, which seeks to facilitate the massive analysis of patient data, thanks to Artificial Intelligence (AI) to prevent breast cancer. Specifically, and as explained by ODELIA’s management, this project aims to “overcome the obstacles to the collection of information on the health of patients with guarantees”, to advance in early, better and more accurate diagnosis and treatment of different pathologies, especially of some types of cancer, such as breast cancer.

Ribera is a leader in the diagnosis and treatment of breast cancer, with a Breast Area headed by Dr. Julia Camps and made up of a multidisciplinary team of almost a hundred professionals. The participation of the Ribera health group, through its foundation, in this European project allows it to form part of the team that is already designing open source software to develop the first clinically useful AI algorithm for the detection of breast cancer in magnetic resonance imaging.

About Odelia

The ODELIA consortium brings together partners from twelve academic institutions and industrial partners from across Europe, namely: European Institute for Biomedical Imaging Research (Austria), Aachen University Hospital (Germany), Vall d’Hebron Institute of Oncology (Spain), Mitera Hospita (Greece), Radboud University Medical Center (The Netherlands), University Medical Center Utrecht (The Netherlands), the Ribera Health Group (Spain), Fraunhofer Institute for Digital Medicine MEVIS (Germany), OSMIS (Belgium), Technische Universität Dresden (Germany), University of Zurich (Switzerland) and the University of Cambridge (UK). The project will run until December 2027 and has funding of around €8.6 million.